美女免费一级视频在线观看

    1. <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit.

      As part of the executive transition, Weber will retire in June 2026 after 12 years at the drugmaker. 

      Prior to joining the Japanese pharma giant, Weber worked at GSK for more than two decades, leaving in March 2014 as president and GM of vaccines.

      Since assuming the CEO post in 2015, Weber has guided Takeda through a number of critical business developments.

      Key among these were the acquisition of Shire for $62 billion as well as the sale of its Xiidra dry-eye business to Novartis for $5.3 billion.

      The company has encountered struggles in recent years amid slumping profits and challenges from generics, which prompted Weber to unveil a $900 million restructuring effort last May. 

      In subsequent months, Takeda cut jobs or transferred U.S.-based staff and offered early retirement options to slash costs. 

      The decision to elevate Kim, who has been with Takeda since it bought Shire in 2019, came after a multi-year succession planning process as well as a unanimous vote by the drugmaker’s board of directors.

      Prior to joining Shire, Kim spent 18 months in leadership at Baxalta and more than 13 years at Baxter International. 

      Kim will now be proposed as a candidate for election to the company’s board at the annual shareholder meeting next year. Meanwhile, Weber will leave the board after retiring from the top spot. 

      In a post on her LinkedIn profile, Kim thanked Weber and Takeda’s leadership team for their support as she becomes the next in line to helm the drugmaker.

      “Today, nothing is changing and I remain focused on serving our existing patients and stakeholders plus bringing our innovative pipeline to new patients in the U.S.,” she wrote. “We have a significant number of programs in Phase 3 that are expected to read out during 2025, and we need to gear up for the launches that are planned for the second half of 2026.”

      Notably, Kim is set to become one of only a handful of women CEOs leading Big Pharma companies, joining contemporaries like Vertex Pharmaceuticals’ Reshma Kewalramani, MD and GSK’s Dame Emma Walmsley.

      Weber’s announcement on Thursday morning also came shortly after Takeda released its latest earnings report. 

      The drugmaker posted quarterly profits that missed analyst estimates, though the company raised its full-year earnings guidance.

      Over the past year, the company’s stock has dropped nearly 5%.